Afatinib in Previously Untreated Metastatic NSCLC With Nonresistant EGFR Mutations

2018-05-18T12:06:49+00:00

Originally Published by Matthew Stenger, May 10, 2018 http://www.ascopost.com/issues/may-10-2018/afatinib-metastatic-egfr-nsclc/?email=b06b278eaf7aaba05ed6c8b82aaf99e8600bf3c9459683239621c4e2cae09675 In the Clinic provides overviews of novel oncology agents, addressing indications,

Afatinib in Previously Untreated Metastatic NSCLC With Nonresistant EGFR Mutations2018-05-18T12:06:49+00:00